The use is narrower than the search phrase
The approval record dates Vyleesi (bremelanotide) to June 21, 2019; the approved use described here was checked against the FDA-approved prescribing information, called the label, on November 3, 2026.
It covers women before menopause whose low sexual desire causes marked distress or difficulty in relationships.
The low desire must have developed after a time without that problem. It must occur across partners, settings and kinds of sexual stimulation.
HSDD means hypoactive sexual desire disorder, the label’s name for the kind of troubling low desire being assessed.
The low desire must not be explained by a medical or mental health condition, relationship problems, or the effects of a medicine or other drug.
That last part can be easy to miss in a short advertisement. It means the conversation has to make room for possible explanations, rather than moving straight from “low desire” to a product name.
What acquired and generalized mean
Acquired describes a change after a period when desire was not a problem.
Generalized means the low desire occurs across kinds of stimulation, settings and partners.
These are terms used by the label. They are not judgments about a person or a relationship. If either word is hard to answer, describe what varies and what stays the same. A clinician can ask for more detail rather than expecting you to arrive with a settled label.
It may help to separate what has changed from how you feel about it. “I have less interest” and “I feel upset about having less interest” answer different parts of the discussion. There is no need to borrow stronger language if it does not match your experience.
Where the approval does not extend
As of November 3, 2026, Vyleesi’s approved use for HSDD does not include men or women after menopause.
Erectile dysfunction and sexual performance enhancement are also outside its approved uses.
Erectile dysfunction means difficulty getting or keeping an erection; it is a different question from the desire diagnosis in the Vyleesi label.
Research that includes a different group does not change the scope of that approval.
When another use is proposed, a useful question is: “Which evidence applies to my situation, and which parts of the label do not?” The answer needs to identify the proposed use and the actual product. It cannot be settled by the phrase peptide therapy alone.
What to take into the discussion
Ask what part of the history points toward this diagnosis. Ask what other explanation is being considered. If a current medicine might be relevant, ask the prescriber to review it rather than making a change from a web page.
An assessment can also leave questions open. It is reasonable to ask what information is missing, how it might be obtained and whether another conversation is needed. A clear answer can be “more discussion first.” It does not have to end with a prescription.
Keep the wording of the proposed goal in view. Does it concern desire, distress about desire, an erection problem, or something else? Naming the goal makes it easier to see whether the evidence being offered addresses the same concern.